Lineage will present at the Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa


CARLSBAD, Calif.–(BUSINESS WIRE)–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, President -CEO of Lineage, will present at the Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa, October 12e, 2022 at 2:15 p.m. PT / 5:15 p.m. ET at Park Hyatt Aviara, Carlsbad, CA. Participation in virtual meetings is available and includes a live stream of the Lineage presentation and the ability to view all conference sessions on demand. Interested parties can visit the Cell & Gene 2022 meeting on the Mesa website for complete conference information, including registration.

The Cell & Gene Meeting on the Mesa is the industry’s premier annual conference bringing together senior executives and leading industry decision makers to advance cutting-edge treatment research. Tackling the barriers to commercialization facing the cell and gene therapy industry today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale and supply chain platforms for advanced therapies. The program includes expert-led panels, extensive partnering capabilities, exclusive networking opportunities and dedicated presentations by leading publicly traded and private companies in the industry. This conference enables key partnerships through more than 3,000 one-on-one meetings while highlighting significant clinical and commercial advancements in the field.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory, reimbursement and manufacturing initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-engineered therapies. Over its 13-year history, ARM has become the global voice of the industry, representing the interests of more than 450 members worldwide, including small and large companies, academic research institutes, major medical centers and patient groups.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary and robust cell therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized and differentiated end-stage human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a way to help the body mount an effective immune response against cancer. Lineage’s clinical programs are in markets with billions of dollars of opportunity and include five allogeneic (“ready-to-use”) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in development for the treatment of geographic atrophy secondary to age macular degeneration, is being developed as part of a worldwide collaboration with Roche and Genentech, a member of the Roche group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in phase 1/2a development for the treatment of acute spinal cord injury; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious diseases, currently in phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neural progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or injury. For more information, visit or follow the company on Twitter @LineageCell.


About Author

Comments are closed.